Skip to Content

Ferriprox Approval History

  • FDA approved: Yes (First approved October 14th, 2011)
  • Brand name: Ferriprox
  • Generic name: deferiprone
  • Dosage form: Tablets
  • Company: ApoPharma Inc.
  • Treatment for: Hemosiderosis

Ferriprox (deferiprone) is an iron chelator indicated for the treatment of patients with transfusional iron overload due to thalassemia syndromes when current chelation therapy is inadequate.

Development History and FDA Approval Process for Ferriprox

Oct 14, 2011Approval FDA Approves Ferriprox to Treat Patients with Excess Iron in the Body
Sep 14, 2011ApoPharma Announces FDA Advisory Committee Recommendation in Favor of Ferriprox (deferiprone) Approval

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.